<unk>  (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and<unk>  (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from<unk>  and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.
Aripiprazole/sertraline
Olanzapine/fluoxetine
Amitriptyline/chlordiazepoxide
Serdexmethylphenidate/dexmethylphenidate
Brief psychotherapy
Naltrexone/bupropion
Aripiprazole lauroxil
Electroconvulsive therapy